Showing 291-300 of 381 results for "".
- FDA Green Lights First Spray-on-Skin Product for Burnshttps://practicaldermatology.com/news/fda-green-lights-first-spray-on-skin-product-for-burns/2457598/The US Food and Drug Administration granted premarket approval to Avita Medical’s Recell, a spray-on-skin that treats second- and third-degree burns in patients aged older than 18 years. The U.S. market launch for the Recell Autologous Cell Harvesting Device (RECELL® System) is
- Experts Call for Improved Identification of "High Burden" Rosacea Patients in Everyday Practicehttps://practicaldermatology.com/news/experts-call-for-improved-identification-of-high-burden-rosacea-patients-in-everyday-practice/2457605/Additional analysis of a global survey conducted and presented earlier this year, as an expert-authored report called Rosacea: Beyond the visible, assists healthcare professionals in identifying the common char
- Compulink Launches Advantage SMART Practice Suite of AI Solutionshttps://practicaldermatology.com/news/compulink-launches-advantage-smart-practice-suite-of-ai-solutions/2457629/Compulink Healthcare Solutions rolled out new artificial intelligence (AI)-enabled features in a release its calling Advantage SMART Practice. Advantage uses AI technology and real-time data from the clinic to completely automate tasks such as billing, along with eliminating steps to improve pati
- Almirall to Acquire Allergan's US Medical Dermatology Unithttps://practicaldermatology.com/news/almirall-to-acquire-allergans-us-medical-dermatology-unit/2457661/Almirall is acquiring a portfolio of five products from Allergan’s Medical Dermatology unit in the United States, conditional to the clearance by the relevant authorities. The portfolio includes Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Ta
- Núria Perez-Cullell Appointed CEO of Pierre Fabre Dermo-Cosmeticshttps://practicaldermatology.com/news/nria-perez-cullell-appointed-ceo-of-pierre-fabre-dermo-cosmetics/2457679/Ms. Núria PerezCullell is the new CEO of The Pierre Fabre Group’s Pierre Fabre Dermo-Cosmetics (PFDC) subsidiary. This appointment will take effect on August 20, 2018. Núria Perez-Cullell will take over from Mr. Eric Ducournau, whose appointment to the position of Pier
- BrightGuard Installs Free Sunscreen Dispensers at New York City Public Pools and Beacheshttps://practicaldermatology.com/news/brightguard-installs-free-sunscreen-dispensers-at-new-york-city-public-pools-and-beaches/2457708/Through its ongoing partnership with non-profit sponsor and donor IMPACT Melanoma and sunscreen provider Coppertone, BrightGuard has installed 134 sunscreen dispensers throughout New York City (NYC) public pools and beaches. BrightGuard—the first aut
- Galderma Global Survey Assesses Burden of Rosaceahttps://practicaldermatology.com/news/galderma-global-survey-assesses-burden-of-rosacea/2457732/Recently released findings from Galderma’s global survey on the true burden of rosacea suggest a need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea. An expert-authored report entitled Rosacea:
- Coming Soon: L'Oréal and SkinCeuticals Unveil CUSTOM D.O.S.Ehttps://practicaldermatology.com/news/coming-soon-loral-and-skinceuticals-unveil-custom-dose/2457841/L'Oréal is unveiling CUSTOM D.O.S.E (D.O.S.E), a personalized skincare service, at Fast Company's Grill in Austin. Developed by L'Oréal's Technology Incubator in partnership with L'Or&eacut
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is
- FDA Accepts Ortho Dermatologics' Filing for IDP-121 Acne Treatment In Lotion Formhttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-idp-121-acne-treatment-in-lotion-form/2457925/The FDA has accepted Ortho Dermatologics' New Drug Application for IDP-121 (tretinoin 0.05%) lotion (Altreno) with a PDUFA action date of Aug. 27, 2018. If approved, Altreno will be the first tretinoin product in lotion form rather than a gel or cream.